FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2001497398> ?p ?o ?g. }

• W2001497398 endingPage "516" @default.
• W2001497398 startingPage "506" @default.
• W2001497398 abstract "BackgroundAn inflammatory reaction in vascular tissue is a potential factor linking restenosis after angioplasty. Although cilostazol, a selective phosphodiesterase type 3 inhibitor that is a unique antiplatelet drug and vasodilator, has been reported to be anti-inflammatory, its effect on the inflammatory action of mononuclear cells homing to endothelial cells is not clearly understood. In this study, whether cilostazol inhibits neointimal formation and improves inflammatory actions by inhibiting sialyl Lewis X (SLX) expression on mononuclear cells and E-selectin expression on endothelial cells was evaluated.MethodsThe effect of cilostazol (1, 3, 10, 30 μM) on expression of E-selectin in human umbilical vein endothelial cells and SLX in rat mononuclear cells stimulated with lipopolysaccharide by immunofluorescence and real-time polymerase chain reaction (n = 3) was studied. Additionally, a double-balloon injury model was used on rat carotid arteries to evaluate vascular intimal hyperplasia. 0.1% cilostazol was administered 3 days before the first balloon injury, and the second balloon injury was performed 7 days after the first injury. Cilostazol administration was continued until rats were sacrificed 14 days after the second angioplasty. The expression of SLX on mononuclear cells and E-selectin on endothelial cells by immunofluorescence (n = 10) and real-time polymerase chain reaction (n = 5) were studied.ResultsCilostazol effectively inhibited the expression of SLX on mononuclear cells and E-selectin on endothelial cells. Cilostazol inhibited the migration of mononuclear cells in neointimal regions and neointimal hyperplasia after balloon injury. The numbers of macrophages and T-lymphocytes and the hyperplasia area in neointimal regions decreased from 71.06 ± 20.04, 1121 ± 244.4 cells per section, 206,400 ± 96,150 mm2 to 29.65 ± 16.73, 374.2 ± 124.5 cells per section, and 101,900 ± 16,150 mm2 due to the administration of cilostazol.ConclusionsThese results demonstrate that the protective effect of cilostazol against neointimal hyperplasia may be mediated by its anti-inflammatory actions of mononuclear cells homing to endothelial cells by decreasing SLX and E-selectin expression. An inflammatory reaction in vascular tissue is a potential factor linking restenosis after angioplasty. Although cilostazol, a selective phosphodiesterase type 3 inhibitor that is a unique antiplatelet drug and vasodilator, has been reported to be anti-inflammatory, its effect on the inflammatory action of mononuclear cells homing to endothelial cells is not clearly understood. In this study, whether cilostazol inhibits neointimal formation and improves inflammatory actions by inhibiting sialyl Lewis X (SLX) expression on mononuclear cells and E-selectin expression on endothelial cells was evaluated. The effect of cilostazol (1, 3, 10, 30 μM) on expression of E-selectin in human umbilical vein endothelial cells and SLX in rat mononuclear cells stimulated with lipopolysaccharide by immunofluorescence and real-time polymerase chain reaction (n = 3) was studied. Additionally, a double-balloon injury model was used on rat carotid arteries to evaluate vascular intimal hyperplasia. 0.1% cilostazol was administered 3 days before the first balloon injury, and the second balloon injury was performed 7 days after the first injury. Cilostazol administration was continued until rats were sacrificed 14 days after the second angioplasty. The expression of SLX on mononuclear cells and E-selectin on endothelial cells by immunofluorescence (n = 10) and real-time polymerase chain reaction (n = 5) were studied. Cilostazol effectively inhibited the expression of SLX on mononuclear cells and E-selectin on endothelial cells. Cilostazol inhibited the migration of mononuclear cells in neointimal regions and neointimal hyperplasia after balloon injury. The numbers of macrophages and T-lymphocytes and the hyperplasia area in neointimal regions decreased from 71.06 ± 20.04, 1121 ± 244.4 cells per section, 206,400 ± 96,150 mm2 to 29.65 ± 16.73, 374.2 ± 124.5 cells per section, and 101,900 ± 16,150 mm2 due to the administration of cilostazol. These results demonstrate that the protective effect of cilostazol against neointimal hyperplasia may be mediated by its anti-inflammatory actions of mononuclear cells homing to endothelial cells by decreasing SLX and E-selectin expression." @default.
• W2001497398 created "2016-06-24" @default.
• W2001497398 creator A5000849268 @default.
• W2001497398 creator A5012133712 @default.
• W2001497398 creator A5016084389 @default.
• W2001497398 creator A5025464092 @default.
• W2001497398 creator A5038239367 @default.
• W2001497398 creator A5042183736 @default.
• W2001497398 date "2012-02-01" @default.
• W2001497398 modified "2023-09-30" @default.
• W2001497398 title "Cilostazol suppression of arterial intimal hyperplasia is associated with decreased expression of sialyl Lewis X homing receptors on mononuclear cells and E-selectin in endothelial cells" @default.
• W2001497398 cites W1496638723 @default.
• W2001497398 cites W1969592317 @default.
• W2001497398 cites W1970181957 @default.
• W2001497398 cites W1971267581 @default.
• W2001497398 cites W1984459733 @default.
• W2001497398 cites W1986568799 @default.
• W2001497398 cites W1988719433 @default.
• W2001497398 cites W1994049232 @default.
• W2001497398 cites W1996282767 @default.
• W2001497398 cites W2003431470 @default.
• W2001497398 cites W2005583229 @default.
• W2001497398 cites W2021877641 @default.
• W2001497398 cites W2024884012 @default.
• W2001497398 cites W2051763029 @default.
• W2001497398 cites W2052893447 @default.
• W2001497398 cites W2054759649 @default.
• W2001497398 cites W2065623224 @default.
• W2001497398 cites W2068149589 @default.
• W2001497398 cites W2068769100 @default.
• W2001497398 cites W2074652197 @default.
• W2001497398 cites W2076552301 @default.
• W2001497398 cites W2082034727 @default.
• W2001497398 cites W2083897900 @default.
• W2001497398 cites W2091990546 @default.
• W2001497398 cites W2096678608 @default.
• W2001497398 cites W2109478329 @default.
• W2001497398 cites W2113471179 @default.
• W2001497398 cites W2119380659 @default.
• W2001497398 cites W2129826639 @default.
• W2001497398 cites W2141530586 @default.
• W2001497398 cites W2143326551 @default.
• W2001497398 cites W2150856103 @default.
• W2001497398 cites W2413870938 @default.
• W2001497398 cites W2461823425 @default.
• W2001497398 cites W4213141530 @default.
• W2001497398 doi "https://doi.org/10.1016/j.jvs.2011.07.087" @default.
• W2001497398 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22264805" @default.
• W2001497398 hasPublicationYear "2012" @default.
• W2001497398 type Work @default.
• W2001497398 sameAs 2001497398 @default.
• W2001497398 citedByCount "12" @default.
• W2001497398 countsByYear W20014973982012 @default.
• W2001497398 countsByYear W20014973982013 @default.
• W2001497398 countsByYear W20014973982014 @default.
• W2001497398 countsByYear W20014973982016 @default.
• W2001497398 countsByYear W20014973982017 @default.
• W2001497398 countsByYear W20014973982018 @default.
• W2001497398 countsByYear W20014973982019 @default.
• W2001497398 countsByYear W20014973982021 @default.
• W2001497398 countsByYear W20014973982023 @default.
• W2001497398 crossrefType "journal-article" @default.
• W2001497398 hasAuthorship W2001497398A5000849268 @default.
• W2001497398 hasAuthorship W2001497398A5012133712 @default.
• W2001497398 hasAuthorship W2001497398A5016084389 @default.
• W2001497398 hasAuthorship W2001497398A5025464092 @default.
• W2001497398 hasAuthorship W2001497398A5038239367 @default.
• W2001497398 hasAuthorship W2001497398A5042183736 @default.
• W2001497398 hasBestOaLocation W20014973981 @default.
• W2001497398 hasConcept C126322002 @default.
• W2001497398 hasConcept C137061746 @default.
• W2001497398 hasConcept C185592680 @default.
• W2001497398 hasConcept C202751555 @default.
• W2001497398 hasConcept C2777628954 @default.
• W2001497398 hasConcept C2778095995 @default.
• W2001497398 hasConcept C2778283817 @default.
• W2001497398 hasConcept C2778583881 @default.
• W2001497398 hasConcept C2779751240 @default.
• W2001497398 hasConcept C2779820409 @default.
• W2001497398 hasConcept C2992686903 @default.
• W2001497398 hasConcept C55493867 @default.
• W2001497398 hasConcept C71924100 @default.
• W2001497398 hasConceptScore W2001497398C126322002 @default.
• W2001497398 hasConceptScore W2001497398C137061746 @default.
• W2001497398 hasConceptScore W2001497398C185592680 @default.
• W2001497398 hasConceptScore W2001497398C202751555 @default.
• W2001497398 hasConceptScore W2001497398C2777628954 @default.
• W2001497398 hasConceptScore W2001497398C2778095995 @default.
• W2001497398 hasConceptScore W2001497398C2778283817 @default.
• W2001497398 hasConceptScore W2001497398C2778583881 @default.
• W2001497398 hasConceptScore W2001497398C2779751240 @default.
• W2001497398 hasConceptScore W2001497398C2779820409 @default.
• W2001497398 hasConceptScore W2001497398C2992686903 @default.
• W2001497398 hasConceptScore W2001497398C55493867 @default.
• W2001497398 hasConceptScore W2001497398C71924100 @default.
• W2001497398 hasIssue "2" @default.
• W2001497398 hasLocation W20014973981 @default.
• W2001497398 hasLocation W20014973982 @default.

• next